All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Clinical Drug Pipeline Developments & Deals by Meissa Vaccines

All Data

Filters

refresh

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

refresh

Companies By Therapeutic Area

Development Status

Meissa Vaccines

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

Contact the Supplier

Lead Product(s): MV-014-210

Therapeutic Area: Infections and Infectious Diseases Product Name: MV-014-210

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands.

Meissa Vaccines

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine, MV-012-968

Contact the Supplier

Lead Product(s): MV-012-968

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

With Fast Track Designation, Meissa is eligible for early and frequent interactions with FDA reviewers to discuss all aspects of the clinical development plan for MV-012-968.